Hope Rugo, MD, clinical professor, department of medicine, and director of Breast Oncology Clinical Trials Program, at University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the role of immunotherapy in breast cancer.
HER2-Low and -Ultralow Populations Benefit from T-DXd in HR+ mBC
November 13th 2024During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO, discussed data from the DESTINY-Breast04 and DESTINY-Breast06 trials for HER2-low breast cancer in the second article of a 2-part series.
Read More